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A B S T R A C T
In the present article, we review publications from the previous year in the following 3 areas: clinical
cardiology, geriatric cardiology, and heart failure and transplantation. Among the new developments in
clinical cardiology are several contributions from Spanish groups on tricuspid and aortic regurgitation,
developments in atrial ﬁbrillation, syncope, and the clinical characteristics of heart disease, as well as
various studies on familial heart disease and chronic ischemic heart disease. In geriatric cardiology, the
most relevant studies published in 2014 involve heart failure, degenerative aortic stenosis, and data on
atrial ﬁbrillation in the geriatric population. In heart failure and transplantation, the most noteworthy
developments concern the importance of multidisciplinary units and patients with preserved systolic
function. Other notable publications were those related to iron deﬁciency, new drugs, and new devices
and biomarkers. Finally, we review studies on acute heart failure and transplantation, such as inotropic
drugs and ventricular assist devices.
 2014 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L.U. All rights reserved.
Actualizacio´n 2014 en cardiologı´a clı´nica, cardiologı´a geria´trica e insuficiencia
cardiaca y trasplante
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R E S U M E N
Han sido muchos los trabajos publicados en el u´ltimo an˜o en las 3 a´reas recogidas en este artı´culo:
cardiologı´a clı´nica, cardiologı´a geria´trica e insuﬁciencia cardiaca y trasplante. Entre las novedades
en cardiologı´a clı´nica se han incluido aportaciones de grupos espan˜oles en valvulopatı´a tricu´spide y
ao´rtica, novedades en ﬁbrilacio´n auricular, sı´ncope y sobre las caracterı´sticas clı´nicas de los cardio´patas,
ası´ como varios trabajos sobre cardiopatı´as familiares y sobre cardiopatı´a isque´mica cro´nica. Respecto a
la cardiologı´a geria´trica, los estudios ma´s relevantes durante el u´ltimo an˜o esta´n centrados en
insuﬁciencia cardiaca, estenosis ao´rtica degenerativa y tambie´n datos de ﬁbrilacio´n auricular en la
poblacio´n anciana. En insuﬁciencia cardiaca y trasplante, las novedades ma´s destacables se centran en la
importancia de las unidades multidisciplinares, ası´ como en los pacientes con funcio´n sisto´lica
preservada. Tambie´n se destacan aportaciones en relacio´n con el de´ﬁcit de hierro, los nuevos fa´rmacos y
los nuevos dispositivos y biomarcadores. Por u´ltimo se resen˜an trabajos centrados en insuﬁciencia
cardiaca aguda y trasplante, como los fa´rmacos inotro´picos y los dispositivos de asistencia ventricular.
 2014 Sociedad Espan˜ola de Cardiologı´a. Publicado por Elsevier Espan˜a, S.L.U. Todos los derechos reservados.* Corresponding author: Servicio de Cardiologı´a, Hospital Universitario Virgen del Rocı´o, Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013 Sevilla, Spain.
E-mail address: gbaron@jet.es (G. Baro´n-Esquivias).
http://dx.doi.org/10.1016/j.rec.2014.12.008
1885-5857/ 2014 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L.U. All rights reserved.
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Valvular Diseases
Surgical repair results were described in a study of 119 patients
with tricuspid regurgitation; the cause was organic in 40%. Most
lesions were repaired using de Vega annuloplasty (73%). The
mortality and complication results were satisfactory, and age and
cardiopulmonary bypass time persistently appeared as predictive
factors of death and residual tricuspid regurgitation. As in other
series, this study suggested that the indications are restrictive and
limited to those patients with more advanced or organic valvular
disease. Consequently, there are relatively few cases for the wide
period considered; on average, an intervention was performed on
tricuspid regurgitation in only 6.4% of the 133 valvular disease
patients treated annually. Moreover, the high proportion of
patients with organic valvular disease or previous surgery
increased the risk of the intervention.1
Various studies on percutaneous aortic valve implants have
been published during the year. One particularly notable article
reported the results of percutaneous aortic valve implantation in
patients with porcelain aorta.2 This study presented short- and
long-term results after percutaneous aortic valve implantation
with the Medtronic CoreValveW System in patients with
porcelain aorta. A total of 449 patients were included from
3 academic centers. The prevalence of porcelain aorta was 8%.
Bearing in mind the lack of uniformity in the deﬁnitions used,
atherosclerosis of the aorta was found in up to one-third of
octogenarians who underwent cardiac surgery interventions, and
the frequency of true porcelain aorta was between 1% and 5%
(Figure).
In one of the largest series published, Forteza et al3 presented
the results of valve-sparing surgery in 51 patients with bicuspid
aortic valve and aneurysm of the aortic root or ascending aorta.
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Figure. Estimation of survival of the study population (n = 449) based on the
presence or absence of porcelain aorta.loss, or perforations were not considered candidates for repair. At
the end of follow-up, no patients had died and all patients were
free of aortic regurgitation > II and reintervention on the aortic
valve. Thus, this surgical technique is an option in selected patients
with bicuspid aortic valve and shows excellent medium-term
results.3
Atrial Fibrillation
Atrial ﬁbrillation and its consequences is one of the most
prevalent conditions in clinical cardiology, affecting up to 21% of
patients attending cardiology clinics. This anomaly was studied in
several important articles published in 2014. The FIATE study,4
a cross-sectional, multicenter study of patients attending Spanish
health centers, included 2070 patients with a mean age of 74 years
(50.7% women) with atrial ﬁbrillation routinely attended in
primary care. The therapeutic strategy in 4 out of 5 patients
was based on heart rate control; the patients showed high use of
oral anticoagulants (84%) and were mainly followed up in primary
care (72%). Finally, the last 3 INR (international normalized ratio)
readings of only 33% of patients were within the therapeutic
range.4
Regarding the diagnosis of this heart condition, Sanmartı´n et al5
analyzed the possible beneﬁts of an information campaign and
atrial ﬁbrillation diagnosis. In this program, individuals  65 years
were invited by letter and through posters and leaﬂets to consult a
specially trained nurse in 3 health centers and the specialized
center of a tertiary referral hospital for 5 consecutive days. The
selected population had no history of atrial ﬁbrillation or ﬂutter.
The program included a brief medical history, blood pressure
reading, and palpation of the radial or humeral pulse for at least
15 seconds. If the nurse detected any pulse irregularity, an
electrocardiogram was performed and immediately analyzed by
a family physician. In 1532 participants with a mean (SD) age of
72.5 (6.5) years, there were 17 cases of newly diagnosed atrial
ﬁbrillation (1%). The authors concluded that, while the beneﬁts of
this type of campaign are difﬁcult to estimate in terms of the health
education provided, this approach detects few asymptomatic cases
of atrial ﬁbrillation in an at-risk Spanish population.5
During 2014, new data were published on the use of new direct
oral anticoagulant drugs in the prevention of embolisms in
patients with atrial ﬁbrillation. The ENGAGE AF-TIMI 48 study6
showed how edoxaban, a new once-daily factor Xa inhibitor, has
been successfully added to this group of drugs. This clinical trial
included 21 105 patients followed up for 2.8 years and compared
the 60 mg and 30 mg one-a-day edoxaban regimens. Edoxaban
was noninferior to well-controlled warfarin in the prevention of
stroke and systemic embolism. Compared with warfarin, edoxaban
was associated with a more consistent dose-related reduction in
bleeding, showing itself to be a new therapeutic option, effective
and safer than standard warfarin therapy.6
For direct oral anticoagulant drugs already used in clinical
practice, many studies have conﬁrmed the results of the initial
clinical trials, reafﬁrming the beneﬁt and safety of their correct use
in preventing stroke and peripheral embolisms in patients with
nonvalvular atrial ﬁbrillation. The use of direct oral anticoagulants
is absolutely contraindicated in patients with mechanical aortic or
mitral valve prostheses (in the 7 days before randomization or in
the previous 3 months), as indicated by the results of the RE-ALIGN
study.7 This phase II clinical trial examined the efﬁcacy and safety
of dabigatran in these 2 types of patients. After the inclusion of
252 patients, the trial was prematurely terminated due to an
excess of embolic and bleeding events in the patients treated with
dabigatran. Safety analysis showed that, dabigatran was associated
with an increased risk of bleeding events. Analysis of the efﬁcacy of
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revealed a nonsigniﬁcant trend toward an increased risk of embolic
events, deﬁned as a composite of death, stroke, transient ischemic
attack, systemic embolism, or myocardial infarction, which could
be largely explained by the higher number of cerebrovascular
events.7
Syncope
The use of the implantable loop recorder has been expanded for
the diagnosis of patients with syncope. One notable, prospective,
multicenter Spanish registry included patients who received an
implantable loop recorder from 2006 to 2008. There were 1-year
follow-up data for 91% of participants. Of the 743 patients included
(55.6% men; mean age, 64.9 years), 31% had heart disease and
24.6% had bundle branch block. The indication for implantation
was syncope in 76.4% of patients. In a third of the patients, a ﬁnal
diagnosis was obtained with the implantable loop recorder,
independent of the baseline characteristics. There were 414 events
in 48% of the patients (325 patients) and a ﬁnal diagnosis was
obtained in 230 of them (70.8% of patients with events and 33.1% of
patients with follow-up). The most frequent diagnosis was syncope
secondary to bradyarrhythmia, without differences among
patients with heart disease, bundle branch block, or normal
heart. Patients with recurrent syncope as the indication for
implantation had more events during follow-up.8
Clinical Characteristics of Patients With Heart Disease
Mejı´a-Lancheros et al9 published a subanalysis of the PRE-
DIMED study, which included 7447 people with cardiovascular risk
factors; the lower age limit was 55 years for men and 60 years for
women. The study analyzed if socioeconomic differences, as
gauged by educational level, determined the treatment prescribed
for diabetes, hypertension, or dyslipidemia. Multivariate analysis
failed to show differences between participants with moderate or
low educational levels and the treatment received, suggesting that
free universal health care effectively reduces possible treatment
differences related to socioeconomic status.
Barrios et al10 analyzed the clinical proﬁle and management of
hypertensive patients seen in primary care according to age, taking
data from the PRESCAP 2010 study. Of the 12 961 patients
included, 440 (3.4%) were younger than 45 years, 1672 (12.9%)
were 45 to 54 years of age, and 10 849 (83.7%) were older than
54 years. Systolic blood pressure increased as patients aged, along
with the proportion of patients with dyslipidemia, diabetes mellitus,
target organ damage, and cardiovascular disease. In contrast,
increased patient age was accompanied by decreases in diastolic
blood pressure and the proportion of patients who smoked and with
family history of cardiovascular disease. Blood pressure control
worsened as patient age increased (62.3%, 54.8%, and 44.0%,
respectively; P = .0001), despite greater use of combination therapy
(43.4%, 49.9%, and 66.4%; P = .0001). As patient age increased,
physicians made fewer changes to the antihypertensive treatment
in response to poor blood pressure control (36.3%, 35.1%, and 27.5%;
P = .0001). The most frequent response in all patients was to add
another drug, followed by a dose increase, and the least frequent
approach was to modify the pharmacological treatment, without
signiﬁcant differences according to age.
Genetic and Familial Heart Diseases
Selection of notable studies in this ﬁeld is difﬁcult due to the
enormous volume published and the important work performedby various Spanish groups in this area. Villacorta et al11 describe
the case of a patient who had frozen embryos from in vitro
fertilization who wanted only those free from mutation to be
implanted. A genetic study showed that the patient had inherited
2 mutations in the same gene, 1 from each parent. Thus, all her
descendents would have one or the other mutation. In their
experience, almost half of patients, both carriers and noncarriers of
the mutation, are in reproductive age and were advised on
reproductive issues. In addition, the penetrance of hypertrophic
cardiomyopathy is high. There are various legal limitations in
certain professions (police, ﬁre service, pilots, etc) and competitive
athletics for patients who develop this disease. Thus, career and
sporting counseling should be given to families with this genotype
before professions are selected.
The second work12 was a cost-utility analysis of a genetic study
of patients with hypertrophic cardiomyopathy in the units of the
Son Lla`tzer and Puerta de Hierro hospitals from 2008 to 2012. The
authors calculated the costs of the genetic study and the costs of
clinical visits and associated tests that could be saved by
dispensing with follow-up in genotype-negative families. The
overall expense was low, at just s135 per family who underwent
the genetic study. In addition, latest-generation sequencing
techniques that allow analysis of more genes at a lower cost are
likely to further reduce the cost of the method and tip the scale
toward a net economic saving. Of the sample, 24% were younger
than 30 years and could be advised on their professional and
sporting activities. Naturally, the beneﬁt is also signiﬁcant for
families negative for the genotype. As well as the lack of need for
lifelong follow-up, participants who learn that they are not carriers
of the mutation are free to pursue any type of physical or
professional activity and have no reproductive implications.
Chronic Coronary Artery Disease
The CLARIFY study13 involves an international registry with a
planned follow-up of 5 years that is being performed in
41 countries in outpatients with stable coronary artery disease.
During 2014, the baseline results of the CLARIFY study in Spain
were published and compared with those of other Western
European countries. Worldwide, 33 248 patients were included, 14
726 in western Europe and 2257 in Spain.13 In Spain, the mean age
was 65 years, slightly lower than that of other western countries,
and most participants were men (81%). Compared with the rest of
western Europe, the Spanish cohort had a higher frequency of
diabetes mellitus (34% vs 25%; P < .0001), myocardial infarction
(64% vs 60%; P < .0001), and stroke (5% vs 3%; P = .0007) and a lower
frequency of family history of coronary artery disease (19% vs 31%;
P < .0001). The most common treatments in the Spanish sample
were lipid-lowering drugs (96%), aspirin (89%), and beta-blockers
(74%). Thus, Spanish patients with coronary artery disease are
similar to those of the other European countries participating in
the registry and appear to be representative of the Spanish
population with coronary artery disease.
GERIATRIC CARDIOLOGY
In this area, the most relevant studies of 2014 concern heart
failure (HF), degenerative aortic stenosis, and atrial ﬁbrillation. In
HF, special emphasis has been placed on reducing the number of
hospital admissions, the main determinant of the health care cost
of HF patients. The developments in aortic stenosis are derived
from transcatheter aortic valve implantation, while those in atrial
ﬁbrillation concentrate on comparison of the effectiveness and
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Health care reform in the United States has identiﬁed reduced
hospitalizations due to HF as a priority for achieving a saving in the
costs of the health care system. Thus, funding has been reduced for
hospitals exceeding certain established standards. Accordingly,
and because the prevalence of HF increases with age, Bourge et al14
performed a subanalysis of the classic DIG (Digitalis Investigation
Group) study that analyzed the role of digoxin in reducing
hospitalization of ambulatory patients older than 65 years with HF
and left ventricular systolic dysfunction (ejection fraction < 45%).
Digoxin reduced all-cause hospitalizations within 30 days follow-
ing discharge in these patients (5.4% vs 8.1%; hazard ratio [HR] =
0.66; 95% conﬁdence interval [95%CI], 0.51-0.86; P = .002), with a
similar 30-day mortality rate (0.7% vs 1.3%; HR = 0.55; 95%CI, 0.27-
1.11; P = .096).
Chaudhry et al15 analyzed the risk factors for hospitalization in
geriatric patients with newly diagnosed HF, determining the
importance of certain geriatric conditions on hospitalization risk,
which reached 7.9 admissions per 10 person-years; the factors
independently associated with hospitalization were diabetes
mellitus, functional class III or IV of the New York Heart Association,
renal failure, slow gait, left ventricular systolic dysfunction,
depression, and muscle weakness. The authors state that these
conditions should be assessed in older patients diagnosed with HF.
The Edwards SAPIEN prosthesis was used in cohort A of the
PARTNER study (the most important randomized trial performed
to date, which compared percutaneous transcatheter and surgical
implantations of aortic prostheses in patients with degenerative
aortic stenosis with high surgical risk). The US CoreValve Pivotal
Trial16 compared surgical aortic valve replacement with implan-
tation of a self-expanding transcatheter bioprosthesis(CoreValveW),
the other prosthesis model most frequently used in Spain. Patients
receiving the transcatheter prosthesis had lower all-cause mortality
at 1 year and reduced cardiovascular and cerebrovascular events,
bleeding, acute renal injury, and atrial ﬁbrillation. In contrast, they
had a higher rate of vascular complications, need for a permanent
pacemaker, and cardiac perforation than the patients who under-
went the surgical intervention.
Dvir et al17 published the largest series of patients with
dysfunctional aortic bioprostheses thus far —40% due to stenosis,
30% due to regurgitation, and 30% due to combined stenosis and
regurgitation—who received a transcatheter valve-in-valve aortic
prosthesis implant. The 30-day mortality in the 459 patients
included was 7.6%. In addition, 1.7% had a stroke and 93% remained
in functional class I or II of the New York Heart Association 1 month
after the implantation. The mean 1-year survival was 83.2%.
Determinants of poor prognosis were the presence of stenosis in
the previous bioprosthesis and a small bioprosthesis size. Finally,
permanent pacemaker implantation, a frequent occurrence after
transcatheter aortic valve implantation, did not increase mortality
or hospitalization in these patients but did negatively impact left
ventricular function, according to results published by Urena
et al.18
In a subanalysis of the ROCKET AF study centered on patients
 75 years old with nonvalvular atrial ﬁbrillation and 2 or more
risk factors for stroke, Halperin et al19 reported a higher rate of
stroke and major bleeding in older than in younger patients and
that the efﬁcacy and safety of rivaroxaban vs warfarin was
unaffected by age. Similar results were obtained in a meta-
analysis20 of randomized studies comparing the new oral antic-
oagulants with warfarin in patients  75 years. The new oral
anticoagulants did not increase the risk of bleeding and reduced or
were similar to warfarin in reducing embolic events.
One ﬁnal noteworthy publication was a consensus document21
with recommendations for deﬁbrillator implantation in patients inthe ﬁnal stages of life. These guidelines are useful for decision
making in this difﬁcult clinical setting and were developed in a
collaboration among the Spanish Society of Geriatric Medicine and
Gerontology (Sociedad Espan˜ola de Geriatrı´a y Gerontologı´a),
Spanish Society for Palliative Care (Sociedad Espan˜ola de Cuidados
Paliativos), and the Section of Geriatric Cardiology (Seccio´n de
Cardiologı´a Geria´trica) of the Spanish Society of Cardiology
(Sociedad Espan˜ola de Cardiologı´a).
HEART FAILURE
The care management of HF is progressing toward new
organizational structures, such as speciﬁc programs based on
integrated and continuous care, for example, multidisciplinary HF
units. Recently, Comı´n et al22 compared the feasibility and
effectiveness of an integrated hospital-primary care program for
managing patients with HF compared with the standard approach
in 56 742 patients. In the 2083 patients included in the program,
vs the 54 659 patients of the other health care areas, there
was a lower risk of death (HR = 0.92; 95%CI, 0.86-0.97; P = .005),
clinically related readmission (HR = 0.71; 95%CI, 0.66-0.76;
P < .001), and rehospitalization for HF.
Heart Failure and Preserved Ejection Fraction
There have been no positive developments in this area, given
the results of the TOPCAT trial.23 In this study, the addition of
spironolactone to optimal medical treatment failed to signiﬁcantly
reduce the composite primary outcome of cardiovascular death,
aborted cardiac arrest, or hospitalization for HF. Post hoc analysis
of TOPCAT revealed marked national differences in the rates of
events. In the Americas (United States, Canada, Brazil, and
Argentina), the primary outcome occurred in 27.3% of patients
in the spironolactone group vs 31.3% in the placebo group (HR =
0.82; 95%CI, 0.69-0.98; P = .026). However, in patients from Russia
and Georgia, the primary outcome occurred in 9.3% of patients
treated with spironolactone vs 8.4% of those treated with placebo
(HR = 1.10; 95%CI, 0.79-1.51; P = .576). Patients included in Russia
and Georgia may not have met the diagnostic criteria for HF and
preserved ejection fraction.
Iron Deﬁciency in Heart Failure
Iron deﬁciency is common in HF patients and intravenous
administration of ferric carboxymaltose improves symptoms and
health-related quality of life in patients with HF and reduced
ejection fraction, in accordance with the results of the FAIR-HF
(FerinjectW Assessment in patients with Iron deﬁciency and
chronic Heart Failure) study. Because there were no long-term
data on the use of this therapeutic strategy, the CONFIRM-HF
(Ferric CarboxymaltOse evaluatioN on perFormance in patients
with IRon deﬁciency in coMbination with chronic Heart Failure)
trial was designed. This study included 304 patients with HF and
reduced ejection fraction and iron deﬁciency (ferritin < 100 ng/mL
or 100-300 ng/mL if transferrin saturation was < 20%). After
52 weeks, treatment with ferric carboxymaltose signiﬁcantly
improved the 6-minute walk test results (mean (SD) difference
between ferric carboxymaltose and placebo: 33 (11) m; P = .002),
symptoms, and health-related quality of life, and signiﬁcantly
reduced the risk of hospitalization due to HF (HR = 0.39; 95%CI,
0.19-0.82; P = .009).24
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Mineralocorticoid receptor inhibitors have improved the
prognosis of HF and reduced ejection fraction but their use is
limited due to hyperkalemia and renal failure. BAY 94-8862 is a
powerful and highly selective nonsteroidal mineralocorticoid
receptor inhibitor. The safety and tolerability of this new molecule
was evaluated in patients with HF and reduced ejection fraction
and mild or moderate chronic renal failure in the ARTS trial.25 In
this study, the use of BAY 94-8862 was associated with a lower
incidence of hyperkalemia (5.3% vs 12.7%; P = .048), less worsening
of renal function, and a signiﬁcant reduction in Nt-proBNP
(aminoterminal brain natriuretic peptide fraction) levels.
The most important progress in HF and reduced ejection
fraction has been the development of ARNIs (angiotensin
receptor-neprilysin inhibitors). LCZ696, the ﬁrst drug of this
new therapeutic class, is composed of 2 molecular fractions:
on the one hand, an inhibitor of the neprilysin enzyme, which
increases natriuretic peptides and, thus, their beneﬁcial effects
(vasodilation, natriuresis, and sympathetic blockade); on the
other hand, valsartan, which inhibits the effects of angiotensin II.
The PARADIGM-HF randomized, double-blind trial26 included
8436 patients with symptomatic HF and left ventricular ejection
fraction  40%. The primary outcome was the composite of
cardiovascular death or hospitalization due to HF. Patients were
randomized to receive LCZ696 200 mg/12 h or enalapril 10 mg/
12 h, in addition to optimal medical treatment. After a mean
follow-up of 27 months, the primary outcome of the study
occurred in 21.8% of patients treated with LCZ696 vs 26.5% of
patients treated with enalapril (HR = 0.80; 95%CI, 0.73-0.87;
P < .001). Compared with enalapril, LCZ696 reduced total mortality
by 16%, cardiovascular death by 20%, and hospitalization due to
HF by 21%. The most frequent adverse events with LCZ696 were
hypotension and mild angioedema; in contrast, LCZ696 reduced
the onset of renal failure, hyperkalemia, and cough compared with
enalapril.27
Devices and Biomarkers
There are more and more devices that incorporate telemonitor-
ing, which sends clinical data recorded to monitoring centers, such
as implantable cardioverter-deﬁbrillators and cardiac resynchro-
nization deﬁbrillators. The IN-TIME trial28 evaluated the impact of
telemonitoring on improving the clinical status of patients with
HF. The study included 664 patients with chronic HF with ejection
fraction < 35% and compared those who received implants with
telemonitoring function with control patients. The main evalua-
tion criterion was a composite clinical score. At 12 months follow-
up, 27.2% of patients in the control group experienced clinical
worsening according to the composite outcome compared with
18.9% in the telemonitoring group (P = .013). In addition, the 1-year
mortality was 8.7% in the control group and 3.4% in the
telemonitoring group (P = .0004).
Another area that had generated high expectations is that of
vagal stimulation. The NECTAR-HF trial29 failed to corroborate the
initial data showing improved ventricular remodeling in patients
with HF and reduced ejection fraction. In this randomized study,
right vagal nerve stimulation failed to induce signiﬁcant changes in
ventricular remodeling, functional capacity, or biomarkers. Signif-
icant differences between the groups were only seen in health-
related quality of life.
The use and application of HF biomarkers continues to grow and
there are now new HF- and renal lesion-related biomarkers. One
important development is a new model for stratifying risk in
patients with HF: the BCN Bio-HF calculator. Developed by Lupo´net al,30 this tool incorporates 3 biomarkers: NT-proBNP, high-
sensitivity cardiac troponin T, and high-sensitivity soluble ST2. The
BCN Bio-HF calculator was obtained via analysis of 864 consecutive
outpatients who were followed up for a median of 3.4 years
(305 deaths) and after an initial evaluation of 23 variables included
in 8 independent models.
Acute Heart Failure
Inotrope use in acute HF can cause problems with myocardial
ischemia, arrhythmias, and increased mortality. Omecamtiv
mecarbil is a new inotropic agent that activates myocardial
ATPase to improve the formation of actin-myosin bridges and
increase the ventricular ejection time, contraction force, and
systolic volume, without changing the myocardial consumption of
oxygen or intracellular calcium. In the ATOMIC-AHF study,31which
included 613 patients with left ventricular ejection fraction  40%
and a history of symptomatic HF, 3 increasing doses of omecamtiv
mecarbil intravenously administered for 48 hours were compared
with placebo. The main end point, improvement in dyspnea at 6,
24, and 48 hours, was not reached; however, a more adjusted
analysis of the sample did show a positive tendency with the
higher doses. Doubts regarding the drug and the study arose after it
was determined that there were a higher number of ischemic
events and higher level of troponin I in the omecamtiv mecarbil
group. Thus, we have to wait for phase III studies to conﬁrm its use
for acute HF.
After the expectations created by the RELAX-AHF (Efﬁcacy and
Safety of Relaxin for the Treatment of Acute Heart Failure) trial of
the use of serelaxin in acute HF, efforts have focused on better
understanding its beneﬁcial effects and, particularly, its hemody-
namic action. One recent double-blind and randomized study
evaluated the hemodynamic effects of serelaxin in 71 patients with
acute HF (intravenous perfusion of 30 mg/kg/day for 20 h). Patients
treated with serelaxin had signiﬁcantly reduced pulmonary
capillary pressure and pulmonary arterial pressure, without
changes in the cardiac index. Intravenous cardiac serelaxin was
safe and improved renal function parameters and Nt-proBNP
values.32
Finally, another family of HF drugs activates soluble guanylate
cyclase. This protein plays a key role in the mechanism of action of
nitric oxide because its activation induces the production of cyclic
guanosine monophosphate, which essentially generates vasodila-
tion. In the LEPHT,33 riociguat, a new activator of soluble guanylate
cyclase, had minor effects in patients with pulmonary hyperten-
sion secondary to left ventricular dysfunction. BAY 1021189,
another activator of soluble guanylate cyclase, is currently being
evaluated in 2 phase II studies of patients with HF with reduced
and preserved ejection fraction.
Advanced Heart Failure and Heart Transplantation
Palliative use of intravenous inotropes in patients with
advanced HF is clinically widespread, despite little published
evidence. The LevoRep study34 evaluated levosimendan use in this
type of patient. This randomized, double-blind, and placebo-
controlled study included 120 patients with advanced HF who
received 0.2 mg/kg/min levosimendan for 6 h every 15 days
(4 cycles in total). The study failed to show a signiﬁcant
improvement in functional capacity and health-related quality
of life, the main components of the primary end point.
Levosimendan was safe and associated with a lower rate of
cardiac mortality, indication for cardiac transplant, and the
presence of acute HF.34 The results of the Spanish LION trial are
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in the same patient proﬁle.
Implantations of mechanical ventricular assist devices with
continuous ﬂow pumps continue to increase. The good results
shown by the new third-generation mechanical ventricular assist
devices with continuous ﬂow pumps (HeartWare HVADW) are
widening the indications and, particularly, the deﬁnitive or
destination therapy. The latest annual report of INTERMACS35
reviewed the ﬁrst 8 years of patient enrollment, with more than
10 000 implantations of mechanical ventricular assist devices; the
actuarial survival is still 80% at 1 year and 70% at 2 years.
In heart transplantation, cellular rejection is one of the main
causes of morbidity and mortality. It is still being diagnosed using
invasive methods, such as endomyocardial biopsy. A recent
study36 showed that cellular rejection could be identiﬁed using
a noninvasive biomarker such as microRNA. After including
113 heart transplant recipients, the authors observed 4 microRNAs
with differential serological expressions (miR-10a, miR-31, miR-
92a, and miR-155) and strong correlations with their tissular
expression in cellular rejection. In ROC analysis, miR-10a (AUC
[area under the curve] = 0.976), miR-31 (AUC = 0.932), miR-92a
(AUC = 0.989), and miR-155 (AUC = 0.998) were signiﬁcant
(P < .0001) for all comparisons. This study supports the previous
good results with noninvasive molecular techniques for assessing
cellular rejection in heart transplantation.
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